AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Go back to AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder| AbbVie (NYSE: ABBV) | Delayed: 263.96 -0.06 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.02 | 52 Week High | $68.12 | |||
| Open | $263.29 | 52 Week Low | $50.71 | |||
| Day High | $266.34 | P/E | 57.26 | |||
| Day Low | $262.44 | EPS | $4.61 | |||
| Volume | 8,176,594 | |||||
